Evolent Health Inc Class A (EVH) had a rough trading day for Monday November 11 as shares tumbled 8.4%, or a loss of $-0.85 per share, to close at $9.27. After opening the day at $10.10, shares of Evolent Health Inc Class A traded as high as $10.14 and as low as $9.08. Volume was 1.05 million shares over 8,051 trades, against an average daily volume of n/a shares and a total float of 84.52 million.

InnerWorkings Inc. (INWK) had a rough trading day for Monday November 11 as shares tumbled 10.64%, or a loss of $-0.53 per share, to close at $4.45. After opening the day at $4.88, shares of InnerWorkings Inc. traded as high as $4.89 and as low as $4.22. Volume was 265,852 shares over 2,535 trades, against an average daily volume of n/a shares and a total float of 51.95 million.

It was a tough day for Medical Facilities Corporation (DR:CA) as its stock fell 7.01% to finish the day at $4.64 a share on November 11. That reduces the company’s market cap to 144.33 million on 31.06 million outstanding shares. Medical Facilities Corporation is a component of the the S&P/TSX SmallCap Index.

Coty Inc (NYSE:COTY) – Analysts at Jefferies Financial Group lowered their Q2 2020 earnings per share (EPS) estimates for Coty in a research report issued to clients and investors on Wednesday, November 6th. Jefferies Financial Group analyst S. Wissink now forecasts that the company will post earnings per share of $0.25 for the quarter, down from their previous forecast of $0.27. Jefferies Financial Group has a “Hold” rating and a $10.50 price objective on the stock. Jefferies Financial Group also issued estimates for Coty’s Q4 2020 earnings at $0.20 EPS, Q2 2021 earnings at $0.27 EPS and Q4 2021 earnings at $0.21 EPS.

Hecla Mining (NYSE:HL) – Equities researchers at B. Riley decreased their FY2021 earnings per share estimates for shares of Hecla Mining in a report released on Tuesday, November 5th. B. Riley analyst A. Graf now expects that the basic materials company will earn ($0.15) per share for the year, down from their previous forecast of ($0.14). B. Riley currently has a “Neutral” rating and a $1.80 target price on the stock.

Global Ship Lease Inc (NYSE:GSL) – Stock analysts at B. Riley boosted their FY2019 earnings per share estimates for shares of Global Ship Lease in a research note issued to investors on Thursday, November 7th. B. Riley analyst L. Burke now forecasts that the shipping company will post earnings per share of $1.58 for the year, up from their prior forecast of $1.55. B. Riley has a “Buy” rating and a $15.00 price objective on the stock. B. Riley also issued estimates for Global Ship Lease’s Q4 2019 earnings at $0.32 EPS, Q1 2020 earnings at $0.37 EPS, Q2 2020 earnings at $0.44 EPS, Q3 2020 earnings at $0.53 EPS, Q4 2020 earnings at $0.56 EPS and FY2020 earnings at $1.90 EPS.

Chemours Co (NYSE:CC) – Analysts at Jefferies Financial Group lifted their FY2019 earnings estimates for shares of Chemours in a research report issued to clients and investors on Wednesday, November 6th. Jefferies Financial Group analyst L. Alexander now anticipates that the specialty chemicals company will post earnings of $2.40 per share for the year, up from their previous estimate of $2.35. Jefferies Financial Group also issued estimates for Chemours’ Q4 2019 earnings at $0.46 EPS, FY2020 earnings at $2.70 EPS, FY2021 earnings at $3.50 EPS and FY2022 earnings at $4.35 EPS.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) – Jefferies Financial Group lowered their FY2023 earnings per share estimates for Ultragenyx Pharmaceutical in a research report issued on Wednesday, November 6th. Jefferies Financial Group analyst M. Raycroft now forecasts that the biopharmaceutical company will post earnings of $4.93 per share for the year, down from their previous estimate of $5.07.

ProAssurance Co. (NYSE:PRA) – SunTrust Banks lifted their Q4 2019 earnings per share estimates for ProAssurance in a note issued to investors on Wednesday, November 6th. SunTrust Banks analyst M. Hughes now anticipates that the insurance provider will post earnings per share of $0.18 for the quarter, up from their prior estimate of $0.14. SunTrust Banks also issued estimates for ProAssurance’s Q1 2020 earnings at $0.18 EPS.

Fate Therapeutics Inc (NASDAQ:FATE) – Equities research analysts at Piper Jaffray Companies decreased their FY2019 EPS estimates for shares of Fate Therapeutics in a research note issued on Tuesday, November 5th. Piper Jaffray Companies analyst E. Tenthoff now expects that the biopharmaceutical company will earn ($1.41) per share for the year, down from their previous estimate of ($1.36). Piper Jaffray Companies currently has a “Overweight” rating and a $28.00 target price on the stock. Piper Jaffray Companies also issued estimates for Fate Therapeutics’ Q4 2019 earnings at ($0.35) EPS, Q1 2020 earnings at ($0.35) EPS, Q2 2020 earnings at ($0.37) EPS, Q4 2020 earnings at ($0.41) EPS, FY2020 earnings at ($1.50) EPS, Q1 2021 earnings at ($0.42) EPS, Q2 2021 earnings at ($0.46) EPS, Q3 2021 earnings at ($0.47) EPS and FY2021 earnings at ($1.85) EPS.